Healthcare Services

Global Lung Cancer Diagnostic and Screening Market to Hit $4.03 Billion by 2030 at 9.6% CAGR

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Lung Cancer Diagnostic And Screening Market Expected To Reach Based On Its 2026 Value?

The lung cancer diagnostic and screening market size has experienced robust growth in recent years. Projections indicate it will expand from $2.56 billion in 2025 to $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion is linked to factors such as the high incidence of smoking-related lung cancer, the broad adoption of chest x-ray and CT imaging, the expansion of hospital-based diagnostic facilities, increased recognition of the importance of early lung cancer detection, and the rise of biopsy-based diagnostic confirmation.

The market for lung cancer diagnostics and screening is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this growth during the projection period include the broadening of national initiatives for lung cancer screening, a rise in the uptake of low-dose CT screening, an increasing need for biomarker and blood-based tests, escalating healthcare investments directed towards oncology diagnostics, and enhanced availability of diagnostic imaging centers. Key trends expected during the forecast period encompass the increasing implementation of early lung cancer screening programs, the expanding utilization of advanced imaging and biomarker tests, a heightened emphasis on screening high-risk populations, the proliferation of non-invasive diagnostic methods, and the growing incorporation of multimodal diagnostic pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Factors Are Contributing To The Growth Of The Lung Cancer Diagnostic And Screening Market?

The growing occurrence of lung cancer is anticipated to boost the expansion of the lung cancer diagnostic and screening market in the foreseeable future. This malignant disease, characterized by the uncontrolled spread of aberrant cells within lung tissues, presents with symptoms like coughing, chest pain, and breathing difficulties. Through various tests, including an incisional biopsy and a bronchoscopy, lung cancer diagnosis and screening facilitate the early detection of the condition in patients. Illustratively, data from the American Cancer Society, a US-based government organization, indicated that in January 2023, the United States recorded about 238,340 new instances of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, reports showed 127,070 fatalities attributed to lung cancer (with 67,160 among men and 59,910 among women). Consequently, the increased prevalence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

How Is Segmentation Applied In The Lung Cancer Diagnostic And Screening Market Segment Analysis?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

What Trends Are Shaping The Future Of The Lung Cancer Diagnostic And Screening Market?

Major companies in the lung cancer diagnostic and screening market are dedicating efforts to developing a blood-based test that integrates machine learning, such as whole-genome machine learning, to deliver accessible and convenient lung cancer screening and gain a competitive edge in the sector. Whole-genome machine learning refers to the application of machine learning algorithms for analyzing and interpreting comprehensive sets of genetic data, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test utilizing whole-genome machine learning to analyze cell-free DNA fragments, thereby enhancing lung cancer screening with a 99.7% NPV. This test, designed for routine blood work, pinpoints individuals with potential lung cancer, including early-stage disease. By addressing the low uptake of LDCT screening, the test aims to improve population health.

Who Are The Companies Participating In The Lung Cancer Diagnostic And Screening Market Environment?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Get The Full Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Region Holds The Highest Market Share In The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lung Cancer Diagnostic And Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Market Report

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795